| scholarly article | Q13442814 |
| P50 | author | Gareth J. Morgan | Q61996585 |
| Jacqueline H L Fok | Q87669807 | ||
| Keith Jones | Q42289984 | ||
| Christopher P Wardell | Q56422135 | ||
| P2093 | author name string | Lei Zhang | |
| Faith E Davies | |||
| Suzanne A Eccles | |||
| Paul Workman | |||
| Jonathan J Keats | |||
| Carl S Rye | |||
| Charlotte Pawlyn | |||
| Michael D Bright | |||
| Somaieh Hedayat | |||
| Nicola E A Chessum | |||
| Emmanuel De Billy | |||
| Fabio Mirabella | |||
| Lauren I Aronson | |||
| P2860 | cites work | Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis | Q24655006 |
| Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress | Q24792454 | ||
| DangER: protein ovERload. Targeting protein degradation to treat myeloma | Q26825417 | ||
| Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase | Q28296183 | ||
| Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study | Q33390600 | ||
| KRIBB11 Inhibits HSP70 Synthesis through Inhibition of Heat Shock Factor 1 Function by Impairing the Recruitment of Positive Transcription Elongation Factor b to the hsp70 Promoter | Q33747276 | ||
| High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors | Q33877440 | ||
| Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors | Q79801045 | ||
| Inhibiting the transcription factor HSF1 as an anticancer strategy | Q83588880 | ||
| Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study | Q84013087 | ||
| Guidelines for the welfare and use of animals in cancer research | Q33903753 | ||
| Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology | Q33906319 | ||
| Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis | Q34134476 | ||
| HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers | Q34292197 | ||
| Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101 | Q35251058 | ||
| High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer | Q35546764 | ||
| Hsp90 molecular chaperone inhibitors: are we there yet? | Q35655105 | ||
| Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR | Q35807282 | ||
| A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma | Q35809875 | ||
| Global cellular response to chemotherapy-induced apoptosis | Q37255788 | ||
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms | Q37564751 | ||
| Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation | Q37644930 | ||
| Recent advances and future directions in targeting the secretory apparatus in multiple myeloma | Q38258197 | ||
| Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state | Q38361655 | ||
| Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress | Q39120344 | ||
| State of heat shock factor 1 expression as a putative diagnostic marker for oral squamous cell carcinoma | Q39481890 | ||
| Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib | Q39569161 | ||
| Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis | Q39943208 | ||
| A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability | Q40048204 | ||
| Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells | Q40128062 | ||
| Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. | Q40149301 | ||
| Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. | Q40169580 | ||
| BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth | Q40195083 | ||
| Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells | Q40310345 | ||
| Antimyeloma activity of heat shock protein-90 inhibition. | Q40380103 | ||
| Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. | Q41292799 | ||
| Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. | Q41760786 | ||
| New inhibitor targeting human transcription factor HSF1: effects on the heat shock response and tumor cell survival | Q42237173 | ||
| Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. | Q42492406 | ||
| Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. | Q42548885 | ||
| Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. | Q42940075 | ||
| Progress and Paradigms in Multiple Myeloma | Q44694137 | ||
| Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib | Q44937333 | ||
| The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma | Q46665629 | ||
| Integration of Novel Agents into the Care of Patients with Multiple Myeloma | Q46754093 | ||
| Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen | Q48125728 | ||
| Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. | Q53361004 | ||
| Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. | Q54343391 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2395-2407 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target | |
| P478 | volume | 24 |
| Q96155632 | Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research |
| Q58594721 | HSF1 as a Cancer Biomarker and Therapeutic Target |
| Q90172862 | Immunosurveillance of cancer cell stress |
| Q57793384 | Small Molecule Inhibitors of HSF1-Activated Pathways as Potential Next-Generation Anticancer Therapeutics |
| Q91906119 | The first Autumn School on Proteostasis: from molecular mechanisms to organismal consequences |
Search more.